.webp)
Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The SURPASS-CVOT trial results, analyzed in early 2026, showed that a primary cardiorenal endpoint occurred in only 23.7% of patients treated with Tirzepatide compared to 27.4% for those on other therapies over a median of 46.9 months
Weekly injections that suppress appetite, increase fullness, and help your body use stored fat for energy
In the U.S., its not FDA-approved for general use, meaning its typically available through compounding pharmacies or research supply companies
doi:10.1111/acel.12368 Florou P, Anagnostis P, Theocharis P, et al
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
